Avicenna Anatolian journal of medicine, cilt.2, sa.1, ss.22-24, 2025 (Hakemsiz Dergi)
We report a case of a 49-year-old female with HER2-positive metastatic breast cancer treated with trastuzumab
deruxtecan (T-DXd) after progression on multiple prior lines of therapy. Following the third cycle, she developed
dyspnea and was admitted to the coronary intensive care unit with heart failure and pulmonary edema.
Echocardiography revealed an ejection fraction (EF) of 10-15%. Imaging demonstrated unilateral pleural effusion
and bilateral pulmonary infiltrates. Clinical findings were attributed to T-DXd-induced heart failure, bicytopenia,
and pneumonitis. Despite initial improvement with corticosteroid therapy, long-term follow-up revealed worsening
thrombocytopenia and development of severe pneumonitis, leading to discontinuation of T-DXd. The patient
ultimately succumbed to sepsis. This case highlights the import